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Biocompatible DNA/gold nanoparticle complex with a protective calcium phosphate (CaP) coating was prepared by incubating
DNA/gold nanoparticle complex coated by hyaluronic acid in SBF (simulated body ﬂuid) with a Ca concentration above 2mM.
The CaP-coated DNA complex wasrevealed to havehighcompatibilitywith cells andresistance againstenzymaticdegradation. By
immersion in acetate buﬀer (pH 4.5), the CaP capsule released the contained DNA complex. This CaP capsule including a DNA
complex is promising as a sustained-release system of DNA complexes for gene therapy.
1.Introduction
Gene therapy has been proposed as a novel strategy for the
treatment of refractory disease. However, direct injection
of naked DNA coding a therapeutic gene generally fails
to exhibit a satisfactory therapeutic eﬀect [1, 2]. The low
eﬃciencyisduetothenegativechargeoftheDNAmolecules,
which interferes with the binding of the complex to the
cells. Too large DNA molecules also cause poor uptake by
cells. DNase, which is present everywhere in the living body,
seems to lower the eﬃciency of gene expression. Therefore,
viral vectors have been widely used as carriers to deliver the
therapeutic nucleic acids eﬃciently to the target cells. How-
ever, viral vectors have risks such as random recombination
and immunogenicity [2]. Thus, safer alternative nonviral
v e c t o r ss u c ha sp o l y c a t i o n so rc a t i o n i cl i p i d sh a v eb e e n
explored as transfection mediators [2]. The DNA molecules
can electrostatically associate with the cationic reagents and
form small particles [3]. However, these DNA complexes
are usually positively charged, which invites an adverse
interaction with blood components or cells [4–6]. Moreover,
the therapeutic eﬀect is not satisfactory because of the short
duration of gene expression [7].
Recently, drug delivery systems composed of inorganic
nanoparticles, such as silica nanoparticles [8] or gold
nanoparticles [9], have been developed. Gold nanoparticles
have the advantages of easy preparation and the possibility
of chemical modiﬁcation on the surface [10]. They also
have distinctive optical properties, showing strong surface
plasmon bands from the visible region to the near-IR region
depending on their shape [11, 12]. Absorbed photoenergy is
transformed tothermalenergy,whichstimulatesdrugrelease
[13]. It should, thus, be possible to prepare an optically
responsive DNA release system by binding DNA complexes
to gold nanoparticles through thermodegradable bonds.
However, DNA/gold particle complexes are generally
unstable in plasma because of their positive surface charge
[14] and show nonspeciﬁc side eﬀects with biocomponents
as mentioned above. On the other hand, it is known that
calcium-phosphate-based compounds, which have similar
inorganic components to bone and teeth, are very biocom-
patible, and have been used as biomaterials, such as artiﬁcial
bone or teeth [15]. In addition, they are dissolved and
absorbed by the acid secreted from osteoclasts [16]. Such
biocompatible and biodegradable materials are promising
candidates as novel biocompatible and highly durable drug-
releasing devices [17].
In thisstudy,we developednovel DNA/goldnanoparticle
complexes with protective calcium phosphate (CaP) coating.
The eﬀects of the CaP coating on the protection against
degradation by DNase and suppression of adverse interac-
tions with cells were investigated.2 Journal of Drug Delivery
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Figure 1: Size distribution proﬁle of the gold nanoparticles.
2.Materialsand Methods
2.1. Materials. Chloroauric acid (HAuCl4), sodium boro-
hydride (NaBH4), and 2-aminoethanethiol were purchased
from Wako Pure Chemical Industries, Ltd. Hyaluronic acid
sodium salt (from a microorganism) and YOYO-1 iodide
were obtained from Nacalai Tesque, Inc, and Invitrogen
Corp, respectively. GFP-coding plasmid DNA (pDNA) with
cytomegalovirus promoter was obtained from Clontech
Laboratories, Inc. It was ampliﬁed in Escherichia coli and
puriﬁed with a QIAGEN Plasmid Mega Kit.
2.2. Preparation of DNA/Gold (Au) Nanoparticle Complex.
A solution of 0.01% HAuCl4 (2mL) was reduced using
1μL of 0.38% NaBH4 solution to produce Au nanoparticles.
Five microliters of 330μg/mL pDNA aqueous solution was
mixed with aminoethanethiol (AET) solution (5.6mg/mL,
0.5–8μL; DNA:AET = 1:1.8, 3.6, 7.2, 14.4, and 28.7 (w/w)).
After 10min, 60μL of Au suspension prepared as described
above was added to the DNA/AET solution.
2.3. Preparation of DNA/Au Encapsulated by Calcium Phos-
phate. HA aqueous solution (0.5μL–20μL, 4.8mg/mL) was
added to 67μL of pDNA/AET/Au suspension (pDNA:AET
= 1:7.2 (w/w)). After stirring at room temperature for
30min, 1.5 times concentrated simulated body ﬂuid (SBF)
[18] was added to the pDNA/AET/Au/HA suspension at a
ratio of pDNA:AET:HA = 1:7.2:23.3 (w/w). The mixture
was stirred at 37◦Cf o r2 4h .
2.4. Electrophoresis. A suspension of pDNA/AET/Au/HA
with 1.5 SBF was mixed with an equal volume of 30% NaCl
solution and incubated for 24 hours at 37◦C to dissociate the
DNAcomplex.TheDNAcomplexwasthendilutedwithpure
water to adjust DNA concentration ([DNA] = 2μg/mL), and
dissociation of DNA complex was evaluated by agarose gel
electrophoresis ([agarose gel] = 1%).
2.5. Measurement of ζ-Potential and Size. The sizes of Au
nanoparticles and DNA/AET/Au/HA complex encapsulat-
ed in calcium phosphate were measured by a dynamic light
scattering method (DLS) with a particle analyzer (Malvern
Zetasizer Nano ZS). DNA/AET/Au complex or DNA/
AET/Au/HA complex suspension was diluted with water to
1mL,andζ-potential was measured using the same particle
analyzer.
2.6. SEM-EDS Analysis. DNA/AET/Au/HA encapsulated by
calcium phosphate was dropped onto adhesive carbon tape
and vacuum-dried overnight. The surface was evaluated by
SEM-EDS (JSM-7600F, JEOL Ltd., Japan) operated at 5kV.
2.7. Cytotoxicity. Cytotoxicity of DNA/AET/Au/HA encap-
sulated by calcium phosphate was evaluated by WST-1 assay
as follows: MLC-6 cells, an osteoclast-like cell line derived
fromamouse,wereseededonto24-wellplatesat9 × 103 cells
per well and cultured for 2 days in McCoy 5A media
supplemented with 20% fetal bovine serum (FBS). The
primary growth medium was then replaced with 500μLo f
fresh McCoy 5A with FBS. DNA/AET/Au/HA encapsulated
by calcium phosphate was added to the cells (1.65μgo f
plasmid per well). After incubation for 4 hours at 37◦C,
500μL of fresh medium was added to each well. After an
additional 20h of incubation at 37◦C, the cells were assayed
with Premix WST-1 Cell Proliferation Assay System (Takara
Bio Inc.).
2.8. Cellular Uptake of the Particles. Plasmid DNA was
ﬂuorescently labeled with YOYO-1 at a YOYO-1/nucleotide
ratioof0.1.DNA/AET/Au/HAcomplexwasthenmadeofthe
ﬂuorescent DNA and mixed with 1.5 SBF to be encapsulated
by calcium phosphate (ﬁnal Ca = 2.6mM). It was added to
the cells (1.65μg of plasmid per well). After incubation for
4h o u r sa t3 7 ◦C, 500μL of fresh medium was added to each
well. After an additional 20h of incubation at 37◦C, the cells
were observed by a ﬂuorescence microscopy.
2.9. Enzymatic Degradation of DNA. The protective eﬀect
against the enzymatic degradation of DNA by encapsulation
withcalciumphosphatewasevaluatedusingHindIII(Takara
Bio Inc.) as follows: Hind III (0.5 unit) was added to the
DNA/AET/Au/HA encapsulated by calcium phosphate sus-
pension (DNA = 190ng) in accordance with the instructions
for the reagent. The degradation of DNA was evaluated by
agarose gel electrophoresis ([agarose gel] = 1%).
2.10. Statistical Analysis. Signiﬁcant diﬀerences between two
independent groups were examined by Student’st-test. One-
way analysis of variance (ANOVA) was used to determine
signiﬁcant diﬀerences among six groups.
3.Resultsand Discussion
3.1. Formation of DNA/AET/Au/HA Complex Encapsulated
in Calcium Phosphate. Small gold nanoparticles were readilyJournal of Drug Delivery 3
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Figure 2: ζ-potential of the complex particles composed of (a) DNA, AET, and Au; (b) DNA, AET, Au, and HA.
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Figure 3: Agarose gel electrophoresis proﬁle of the DNA complexes treated in SBF with various Ca concentrations. Complexes were
electrophoresed after dissociation in 15% NaCl. The lowest line represents the result with a DNA complex treated in SBF with [Ca] =
2.6mM and degraded in an acetate buﬀer.
obtained by reduction of HAuCl4 by NaBH4.A ss h o w n
in Figure 1, gold nanoparticles have a relatively narrow
distribution in size with PdI = 0.834. Their number-average
size was 10.5nm with the standard deviation of 1.90nm. It
is known that thiol groups bind to gold nanoparticles [10].
AET was added to positively charge the gold nanoparticle
surface. To decideona suitable ratio ofAET to DNA,various
volumes of AET solution were premixed with DNA solution
andthenaddedtoAususpension.Withincreasing AET/DNA
ratio, ζ-potential of the DNA/AET/Au complex increased
and was saturated at 33mV at AET/DNA = 7.2 (in weight)
(Figure 2(a)). This ratio, where the highest potential was
obtained with the minimal amount of AET, was employed
in the following experiments.
DNA/AET/Au complex was then encapsulated in a CaP
membrane using SBF. An SBF has a similar inorganic
ion concentration to that of human blood plasma and is
supersaturated against hydroxyapatite (Ca ion = 2.5mM). In
this study, 1.5 times concentrated SBF (Ca ion = 3.8mM,
pH 7.25) was used to deposit apatite onto the DNA/gold
complex surfaces. An apatite layer is known to be formed
on bioactive materials with phosphoric acid or carboxylic
acid groups [19]. Hyaluronic acid (HA) was then added to
coat the pDNA/AET/Aucomplex suspension to facilitate the
deposition of calcium phosphate on the complex.
Various amounts of HA were added to DNA/AET/Au
complex (DNA:AET = 1:7.2 in weight), and ζ-potential4 Journal of Drug Delivery
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Figure 4: SEM-EDS analysis of (a) DNA/AET/Au/HA complex; (b) DNA/AET/Au/HA complex encapsulated in calcium phosphate
(prepared in SBF with [Ca] = 2.6mM).
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Figure 5: Size distribution proﬁle of the DNA/AET/Au/HA com-
plex encapsulated in calcium phosphate(prepared in SBFwith Ca =
2.6mM).
was measured. In line with the amount of HA, the surface
charge of the DNA/AET/Au/HAcomplex decreased and was
saturated at −35mV at HA/DNA ratio = 23.3 (in weight).
This ratio, where the ζ-potential reaches the lowest level by
minimum HA (Figure 2(b)), was employed in the following
experiments.
DNA/AET/AucomplexcoatedbyHA(DNA:AET:HA=
1:7.2:23.3 in weight) was added to the SBF, and deposition
of CaP layer on the surface of DNA/AET/Au/HA complex
was attempted. DNA complex suspension was added to 1.5
times concentrated SBF at a ﬁnal Ca concentration of 1.4,
2.0, 2.6, or 3.1mM. To examine the deposition of CaP,
dissociation behavior of the DNA complex in a concentrated
NaCl solution was evaluated. DNA complex immersed in
SBF with 1.4mM Ca ion concentration was dissociated by
concentrated NaCl solution and showed bands at similar
positions to those of DNA complex without SBF. On the
otherhand, the DNAcomplexesimmersed in SBFwith more
than 2.0mM Ca did not show bands from dissociated DNA
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Figure 6: Cytotoxicity of Au nanoparticle and the DNA complexes
with or without calcium phosphate envelope.
molecules. This indicates that CaP could be deposited onto a
surface of DNA complex coated by HA by immersion in SBF
with more than 2.0mM Ca and form a stable encapsulated
complex (Figure 3).
Degradation of the CaP capsule in an acidic solution was
then examined. An equal volume of pH 4.5 acetate buﬀer
was added to the suspension of DNA/AET/Au/HA complex
encapsulated in CaP, which was prepared with 2.6mM Ca.
Afterstirring at 37◦Cfor24h,30% NaClsolutionwasadded.
When it was electrophoresed, a clear band of the dissociated
DNA molecule was observed (Figure 3). This shows that the
DNA complex was coated with a CaP layer, which could
be dissolved in the acidic conditions, and released the DNA
complex encapsulated inside.Journal of Drug Delivery 5
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Figure 7: Cellular uptake of ﬂuorescence-labeled naked DNA and its complex with Au encapsulated with CaP.
In SEM-EDS images, diﬀerences in surface morphology
and composition were observed (Figure 4). Large aggrega-
tion of particles with a diameter of ca. 100nm was seen in
the SEM image of DNA/AET/Au/HA complex, and Au was
detectedin theparticleby EDSanalyses(Figure 4(a)).Onthe
other hand, the DNA/AET/Au/HA complex encapsulated in
CaP was an aggregation of particles of 200nm in diameter.
Calcium and phosphorus were detected in it instead of
Au (Figure 4(b)). It was conﬁrmed that the DNA/AET/Au
complex coated with HA could be encapsulated with CaP
by immersion in SBF. The number average size of the
DNA/AET/Au/HAcomplex encapsulated by CaP suspended
in water was 175nm with the standard deviation of 33.4nm
(Figure 5). The large aggregation of the encapsulated com-
plexwouldbeformedthroughthedrying procedureforSEM
observation.
3.2. Cytotoxicity of DNA Complex Encapsulated in Calcium
Phosphate. Figure 6 shows the cytotoxicity of the DNA/
AET/Au/HAcomplexandtheencapsulatedparticles.Judging
from the WST-1 assay, DNA/AET/Au complex showed
apparent toxicity and only 40% of the cells survived, while
Au itself showed much less toxicity. This was due to the
cationic surface of the DNA/AET/Au complex. On the other
hand,DNAcomplexencapsulatedbyCaPshowed apparently
lower toxicity, and more than 80% of the cells were still
alive. Encapsulation by the biocompatible apatite appeared
to cause diminished toxicity.
3.3. Cellular Uptake of the Particles. Plasmid DNA was
ﬂuorescently labeled by YOYO-1, complexed with gold, and
then packaged by CaP. When they were incubated with
MLC-6 cells, the cells became luminescent, while the cells
treated with naked DNA/YOYO-1 complex did not show the
ﬂuorescence (Figure 7).
3.4. Enzymatic Degradation of DNA Complex Encapsulated in
Calcium Phosphate. Enzymatic degradation behavior of the
DNA molecule was evaluated by incubation with Hind III
followed by agarose gel electrophoresis. DNA molecule in
the DNA/AET/Au/HA complex without CaP was degraded
by the enzyme and showed bands of degradation products.
A smeared band was observed, unlike for the naked DNA
(Figure 8). This was considered to be due to the interaction
of the degraded DNA fragments with the cationic polymer.
DNA complex not completely encapsulated by CaP, which
was prepared in ﬁnal [Ca] = 1.4mM, also showed bands
of degraded products. On the other hand, DNA complex
encapsulated by CaP at more than ﬁnal [Ca] = 2.0 did not
show any DNA fragments (Figure 8). Eﬃcient inhibition of6 Journal of Drug Delivery
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Figure 8: Agarose gel electrophoresis proﬁle of the DNA complex encapsulated in CaP after degradation by Hind III.
DNA degradation by an enzyme by encapsulation with Cap
was conﬁrmed.
CaP-encapsulated DNA/gold nanoparticle has high bio-
compatibility and resistance against enzymatic degradation
and also the releasing property by cellular degradation. It is
expected to be a safe and durable nonviral system for gene
therapy.
4.Conclusion
DNA/goldcomplex was eﬃc i e n t l yi n c l u d e di naC a Pc a p s u l e
by coating the complex with hyaluronic acid followed by
immersioninSBFwithaCaconcentrationabove2mM. Bio-
compatibility and resistance against enzymatic degradation
were apparently enhanced by the encapsulation with CaP.
Incubationof the CaP capsule including DNAcomplex in an
acidicacetatebuﬀerinvitedthereleaseofDNAcomplexfrom
the capsule. This shows the high potential of the CaP capsule
as an injectable slow-release device, which would release the
contained DNA complex by degradation by osteoclasts.
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